S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

CLRB Cellectar Biosciences Inc

3.42

0.08 (2.40%)

After Hours

Last Updated: 06:30:00

Delayed by 15 minutes

Interest in Cellectar increases with private equity purchases

To read the full story on Seeking Alpha, click here.

Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Cellectar Biosciences Charts.

Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Cellectar Biosciences Charts.

Cellectar Biosciences Inc News

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
Wednesday 27 March 2024 (1 month ago) • GlobeNewswire Inc.

Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
Wednesday 20 March 2024 (1 month ago) • GlobeNewswire Inc.

Cellectar Biosciences to Present at the 36th Annual Roth Conference
Thursday 14 March 2024 (2 months ago) • GlobeNewswire Inc.

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
Monday 4 March 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Thursday 15 February 2024 (3 months ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Thursday 15 February 2024 (3 months ago) • Edgar (US Regulatory)

Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Wednesday 7 February 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 2 February 2024 (3 months ago) • Edgar (US Regulatory)

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Thursday 1 February 2024 (3 months ago) • Edgar (US Regulatory)

Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
Tuesday 30 January 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 26 January 2024 (3 months ago) • Edgar (US Regulatory)

Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
Thursday 25 January 2024 (3 months ago) • GlobeNewswire Inc.

More Cellectar Biosciences Inc News Articles

Australian SE All Ordina...

Commonwealth Bank Of Aus...

Woodside Petroleum

Australia And New Zealan...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions